Furthermore, emerging evidence has demonstrated synergistic efficacy between KAT6 inhibitors and Menin inhibitors in preclinical models of ET‐resistant ER+ breast cancer, with a therapeutic effect comparable to that of the novel SERD elacestrant [132]. Here, MEN1 is linked to breast carcinoma.